Guang Yang
Blueprint Medicines (United States)(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Immunodeficiency and Autoimmune Disorders, Chronic Myeloid Leukemia Treatments, RNA modifications and cancer
Most-Cited Works
- → MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia(2012)1,259 cited
- → Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia(2015)917 cited
- → The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis(2013)471 cited
- → A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader(2017)433 cited
- → MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction(2013)408 cited
- → Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia(2014)375 cited
- → A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia(2013)344 cited
- → The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients(2020)327 cited
- → The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia(2014)232 cited
- → Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia(2014)177 cited